Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.
about
Management of women with multiple sclerosis through pregnancy and after childbirthOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisAntiviral Treatment Guidelines for Middle East Respiratory SyndromeMultiple sclerosis and pregnancy: current considerationsPregnancy, sex and hormonal factors in multiple sclerosis.Pregnancy and multiple sclerosis.Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.Pregnancy in multiple sclerosis: a questionnaire study.Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Ocular changes during pregnancy.Multiple sclerosis and pregnancy: maternal considerations.Multiple sclerosis and pregnancy: experience from a nationwide database in Germany.Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancyPregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre studySex and gender issues in multiple sclerosis.Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.Female reproductive issues in multiple sclerosis.Multiple sclerosis and pregnancy: therapeutic considerations.Disease-specific therapy of idiopathic inflammatory demyelinating disorders.Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation.Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.Treatment of multiple sclerosis during pregnancy - safety considerations.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.[Ophthalmic agents during pregnancy and breastfeeding].Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey
P2860
Q26748594-D2081A73-F051-4DA5-9DCB-22B6970850FEQ26777686-59521967-A9AF-483C-BB11-05BA1B0FEC54Q26781374-6EA02AD4-B1F8-45A5-8EB8-E2D809A32614Q26830133-6743DB3A-9547-4C3E-9F4A-D1936557FADCQ30354175-B85B82C3-41A8-4F6F-A36E-937D5BDE032CQ30375612-FE060792-9D3F-48D2-A822-4139F985A52DQ30379738-439B1C85-4949-4F11-9FF6-EC68FDC8C995Q31162052-47C40FA2-D7B7-425E-8330-62408DB0AA4EQ33717231-2714609B-D900-4A86-82A6-FE33F9C3D849Q34028864-B5EC3281-9209-4D4D-8130-3186E2A6D435Q34192777-462FF563-E8FC-4C30-8810-180F53F89342Q34639869-274FF00C-1FE7-49A0-B4B3-4D93AEA08C5AQ36220437-F75AB71D-6F5F-4686-B688-7BB82A36DF41Q36298897-B2C7C0BA-E880-4AC5-8930-2E6BF7D64816Q36367612-0869B20F-4ED6-41E8-BA9D-AEAE8655DA30Q36475245-F3009E35-F135-4951-A4CF-56BBB16176F1Q36515512-3CA3C441-4E9C-49C2-BD2D-342E3C5136BFQ36920201-00962E2A-84EA-4DAF-B87F-34E7AA812140Q36999743-7766D06B-88AD-48A6-9FF6-46175CE0CBD4Q37459065-2ABE7C9D-16A6-48B7-A785-B8718AA367F9Q37547683-110B8E7C-CF8C-41AB-B3E7-B370D428C6BEQ37623205-B1448FA1-A71B-43FA-944A-6D1DA3A45063Q38021743-C71C8C60-D636-4462-893D-8C559E813F12Q38038437-F95A7D12-471B-4993-8025-14E0A578B4DEQ38049628-824D6484-2780-411F-87CD-3573607DF035Q38058831-3363D2F0-FC34-4BEA-9289-B16F6080AFBEQ38074086-3433E354-0164-4D9A-9BDE-D3BA5483D324Q38085336-63027BC0-74DD-4F5A-B0F6-A0C2F2CB54EAQ38125249-BD5BB3FA-D217-46D8-9BCC-FB1171C4DA56Q38245158-95CCA636-64F0-4495-88DA-D4F39437EE51Q38379249-AE3FBCCD-E176-45F0-8C80-CAB79F5D6315Q38883520-20D571E3-E01C-425F-8A96-DA046762ECAAQ39021942-77B65AF4-F10C-4F8A-92FB-EDD27984D37EQ39964998-D93FF5C9-9F17-4BB0-A468-86D28F19B6CCQ44627071-32578B4F-1DA5-4C2F-8860-C75370207586Q45242926-C94DF712-D63E-471A-B67F-97261E853607Q58576027-2A5E726D-8D7E-46DE-BD41-54BA51C330D4
P2860
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Pregnancy outcomes in multiple ...... us interferon beta-1a therapy.
@en
Pregnancy outcomes in multiple ...... us interferon beta-1a therapy.
@nl
type
label
Pregnancy outcomes in multiple ...... us interferon beta-1a therapy.
@en
Pregnancy outcomes in multiple ...... us interferon beta-1a therapy.
@nl
prefLabel
Pregnancy outcomes in multiple ...... us interferon beta-1a therapy.
@en
Pregnancy outcomes in multiple ...... us interferon beta-1a therapy.
@nl
P2093
P2860
P356
P1476
Pregnancy outcomes in multiple ...... us interferon beta-1a therapy.
@en
P2093
Enrica Alteri
Gabrielle Kornmann
Magnhild Sandberg-Wollheim
Margaretha Stam Moraga
P2860
P304
P356
10.1177/1352458510394610
P577
2011-01-10T00:00:00Z